Real-world use of remdesivir for the treatment of patients admitted to Italian hospitals with COVID-19: the nationwide retrospective FADOI-RECOVER study.

Publication date: Jul 08, 2023

Remdesivir is widely used for treatment of SARS-CoV-2 pneumonia. The aim of this study was to evaluate the characteristics of patients with moderate-to-severe COVID-19 treated with remdesivir, and their outcomes during hospitalization. This retrospective observational multicenter study included consecutive patients, hospitalized for moderate-to-severe COVID-19 (September 2020-September 2021), who were treated with remdesivir. One thousand four patients were enrolled, all with onset of symptoms occurring less than 10 days before starting remdesivir; 17% of patients had 4 or more concomitant diseases. Remdesivir was well tolerated, adverse drug reactions (ADRs) being reported in 2. 3% of patients. In-hospital death occurred in 80 patients (8. 0%). The median timing of the first remdesivir dose was 5 days after symptom onset. The following endpoints did not differ according to the time span from the onset of symptoms to the first dose: length of hospitalization, in-hospital death, composite outcome (in-hospital death and/or endotracheal intubation). Advanced age, number of comorbidities ≥ 4, and severity of respiratory failure at admission were associated with poor in-hospital outcomes. In a real-world setting, remdesivir proved to be a safe and well-tolerated treatment for moderate-to-severe COVID-19. In patients receiving remdesivir less than 3 or 5 days from the onset of SARS-CoV-2 symptoms, mortality and the need for mechanical ventilation did not differ from the rest of the sample.

Open Access PDF

Concepts Keywords
10days COVID-19 pneumonia
Hospitalization Internal Medicine
Italian Management of COVID-19
Pneumonia Remdesivir


Type Source Name
disease MESH COVID-19
disease MESH pneumonia
disease MESH adverse drug reactions
disease MESH death
disease VO dose
disease IDO symptom
disease VO time
disease MESH respiratory failure
disease MESH Infectious Diseases
pathway REACTOME Reproduction
disease VO organization
disease MESH infection
disease MESH emergency
disease MESH uncertainty
drug DRUGBANK Oxygen
disease IDO replication
drug DRUGBANK Methylergometrine
disease IDO assay
drug DRUGBANK L-Alanine
disease VO protocol
drug DRUGBANK Ethionamide
disease VO ANOVA
disease VO USA
disease VO population
disease MESH hypertension
disease MESH obesity
disease MESH COPD
drug DRUGBANK Dexamethasone
drug DRUGBANK Baricitinib
drug DRUGBANK Tocilizumab
drug DRUGBANK Heparin
drug DRUGBANK Coenzyme M
drug DRUGBANK Fondaparinux
drug DRUGBANK Rivaroxaban
drug DRUGBANK Apixaban
drug DRUGBANK Edoxaban
drug DRUGBANK Dabigatran
drug DRUGBANK Warfarin
disease MESH sepsis
disease MESH congestive heart failure
disease MESH Coronary heart disease
disease MESH Endocrine disease
disease MESH Gastrointestinal disease
disease MESH Atrial fibrillation
disease MESH Cancer
disease MESH Stroke
disease IDO blood
drug DRUGBANK Alkaline Phosphatase
drug DRUGBANK Creatinine
drug DRUGBANK Metformin
disease MESH Transient ischemic attack
drug DRUGBANK Angiotensin II
drug DRUGBANK Glucagon
disease MESH bradycardia
disease VO Imovax ID
disease VO dead
disease VO effective
drug DRUGBANK Spinosad
disease VO Pla
disease MESH viral infections
drug DRUGBANK Trestolone
disease VO age
disease MESH Acute respiratory distress syndrome
drug DRUGBANK Adenine
disease VO Viruses
drug DRUGBANK Lopinavir
drug DRUGBANK Chloroquine
disease VO report
drug DRUGBANK Ranitidine

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *